PEMF for
Morton's Neuroma
& Metatarsalgia.

July 2026 · 9 min read · Foot Pain Protocol

What Is Morton's Neuroma?

Morton's neuroma is a perineural fibrosis of the third common digital nerve — the branch running between the third and fourth metatarsal heads — caused by repetitive compression and shear stress. The nerve becomes encased in dense fibrous tissue, triggering a cycle of ischemia, axonal demyelination, and neuropathic pain that conventional treatments (corticosteroid injections, footwear modification, orthotics) frequently fail to resolve permanently.

The clinical presentation is characteristic: burning, electric, or shooting pain in the forefoot, often described as "walking on a pebble," worsening with narrow footwear or prolonged standing. The condition disproportionately affects women (15:1 sex ratio) and is under-diagnosed in populations with high occupational foot loading — precisely the demographic driving footfall at Philippine clinic chains.

Metatarsalgia — diffuse forefoot pain from synovitis, second MTP joint instability, Freiberg's disease, or sesamoiditis — shares the same pathological denominator: ischemia, neurogenic inflammation, and impaired periosteal microcirculation at the metatarsal heads. The PEMF protocols for both conditions overlap significantly.

Why Morton's Neuroma Is Systematically Undertreated

Current standard care offers a limited ladder: footwear modification (compliance poor), metatarsal pads (symptomatic only), corticosteroid injection (50–70% short-term relief, significant fat-pad atrophy risk with repeated injections), sclerosing alcohol injections (variable evidence, 3–7 injections required), and surgical neurectomy (70–85% resolution rate but permanent sensory deficit in the web space). None of these address the underlying perilesional ischemia or fibrotic entrapment at the cellular level.

PEMF operates at exactly that level — targeting the perineural microvasculature and axonal regeneration cascade that neither corticosteroids nor orthotics reach.

How PEMF Works on Compressed Peripheral Nerves

The evidence for PEMF on peripheral nerve compression comes from three converging mechanisms:

1. Nitric oxide (NO) upregulation via endothelial NOS — PEMF stimulates eNOS activity, increasing NO production in the endoneurial microvasculature (PubMed 19371845, Strauch et al. 2009). NO is a potent vasodilator; its upregulation reverses the ischemic cycle that sustains perineural fibrosis and axonal dysfunction.
2. VEGF secretion and angiogenesis — The same Strauch 2009 review demonstrated PEMF-induced VEGF secretion drives neovascularisation in hypoxic perineural tissue, restoring nutrient delivery to compressed axons and Schwann cells.
3. Anti-edema and anti-inflammatory effects — PEMF reduces IL-1β and TNF-α-driven perineural edema, directly decreasing the mechanical pressure on the third common digital nerve within its tunnel between the metatarsal heads.

The Evidence Base

PMC5144749 — PEMF vs. Ultrasound RCT (n=40, 4 weeks)

The most directly relevant trial randomized 40 patients with peripheral nerve compression syndrome (carpal tunnel syndrome — an identical nerve-in-tunnel pathological model) to 4 weeks of either PEMF (50Hz, 8mT, 30 min, 3×/week) or therapeutic ultrasound. PEMF was superior across every pre-specified endpoint (all P<0.05):

• VAS pain score reduction: PEMF group significantly greater than ultrasound
• Nerve sensory latency: normalized faster in PEMF group
• Nerve motor latency: normalized faster in PEMF group
• Nerve conduction velocity: improved in PEMF group, no significant change in ultrasound group
• Hand grip strength: greater recovery in PEMF group

The mechanistic parallel to Morton's neuroma is direct: both are peripheral nerve compression syndromes causing ischemic demyelination in a fibrous tunnel. The PEMF parameters that reversed carpal tunnel nerve dysfunction apply to the digital nerve tunnel in the forefoot.

PMC12943413 — Neuropathic Pain Meta-Analysis (13 RCTs, N=688)

A 2026 meta-analysis in Neurology International pooled 13 randomized controlled trials (N=688 patients) examining PEMF for neuropathic pain syndromes. Key findings:

• Overall SMD = −1.01 (95% CI −1.46 to −0.56, P<0.001) — a large effect size
• Radicular neuropathic pain: SMD = −2.35 (very large effect — sciatic/cervical distribution)
• Peripheral neuropathy: SMD = −0.38 (moderate; improvement limited when axonal loss is advanced)

Morton's neuroma pain has both a perineural (compressive-ischemic) and neuropathic component. The large overall effect and strong peripheral nerve mechanism data support PEMF as a first-line non-surgical adjunct.

PMC11914662 — Multicenter RCT (n=91, 2025)

The landmark 2025 multicenter study (5 orthopedic clinics, n=91 completers) confirmed 36% pain reduction vs. 10% in standard care (p<0.0001) and 55% medication reduction vs. 12% in controls — establishing the broader anti-nociceptive and anti-inflammatory profile that underpins PEMF's utility across musculoskeletal and neuropathic pain conditions.

Who Is This Protocol For?

• Confirmed Morton's neuroma (ultrasound or MRI confirmed interdigital neuroma ≥5mm)
• Metatarsalgia with periosteal/synovial inflammation at MTP joints (especially 2nd MTP)
• Post-injection neuroma — patients with persistent or recurrent pain after corticosteroid injection
• Pre-surgical optimization — reducing neural inflammation before surgical neurectomy is contemplated
• High-risk for surgery — diabetic patients with poor wound healing potential, or patients declining neurectomy
• Occupational forefoot overload — nurses, domestic workers, market vendors, hospitality staff with bilateral forefoot pain

Clinical Protocol

Coil Placement

• Primary: Flat applicator placed under the forefoot sole, centered at the 3rd–4th intermetatarsal space
• Secondary (bilateral): Second applicator on dorsal forefoot for transcutaneous penetration of deeper neural structures
• Session frequency: 2–3×/week with rest days between sessions
• Philippine pricing: ₱1,500–₱2,500/session; 10–12 session course standard for confirmed neuroma

PEMF vs. Conventional Treatments

Philippine Market Context

Morton's neuroma and metatarsalgia represent a large, systematically underserved pain segment in the Philippine clinic market for three converging reasons:

• Occupational foot overload: The Philippines has approximately 400,000 registered nurses and 1.3 million BPO workers — two populations with extended standing or walking duties in workplace footwear. Forefoot pain is consistently among the top 3 musculoskeletal complaints in nursing cohort surveys.
• Female workforce dominance: Morton's neuroma is 15× more common in women. With a 57% female labor force participation rate and widespread narrow-toe footwear in the Philippine formal workforce, the addressable population is substantial.
• Diabetic neuropathy overlap: 7–8 million Filipino diabetics have peripheral neuropathy risk. Distal symmetric polyneuropathy (DSPN) mimics Morton's neuroma clinically; many of these patients cycle through podiatry or orthopedics without resolution because the underlying nerve ischemia is not treated. PEMF addresses both presentations simultaneously.
• Surgical avoidance: Filipino patients show high preference for non-surgical solutions. Clinics offering a structured 10–12 session PEMF protocol as an alternative to neurectomy referral capture significant self-pay volume at ₱1,500–₱2,500/session.

Clinics within 70+ Israeli clinics (population: 9M) — now expanding to the Philippines report Morton's neuroma as among the top-10 indications by session volume, with high patient retention due to the non-invasive, zero-downtime treatment profile.

Contraindications

• Active malignancy in the foot or lower extremity
• Electronic implants (pacemaker, cochlear implant, spinal cord stimulator)
• Pregnancy
• Active deep vein thrombosis in the treated limb
• Open wounds or active infection at the treatment site
• Morton's neuroma with complete sensory loss (advanced axonal degeneration — limited regenerative potential)

Frequently Asked Questions

Can PEMF replace corticosteroid injection for Morton's neuroma?

PEMF is positioned as a first-line non-invasive intervention before injection is considered, or as a consolidation treatment after injection has provided temporary relief. The evidence from PMC5144749 shows PEMF outperforming ultrasound (the standard physiotherapy modality) across all nerve endpoints. Corticosteroid injection addresses inflammation but carries fat-pad atrophy risk with repeated use; PEMF has no such risk and can be repeated indefinitely.

How many sessions are needed before a patient notices improvement?

In the peripheral nerve RCT (PMC5144749), measurable nerve conduction improvements were documented after 4 weeks (12 sessions). In clinical practice, patients with early-stage neuroma (Evans Stage I–II) typically report pain reduction after 4–6 sessions. Advanced fibrotic neuromas (Stage III–IV) require the full 16-session course. Setting expectation at 6–8 sessions for initial assessment is appropriate.

Is PEMF evidence specific to Morton's neuroma?

No dedicated Morton's neuroma–PEMF RCT exists as of 2026. The evidence is derived from the carpal tunnel nerve compression model (PMC5144749 — mechanistically identical tunnel compression pathology), the neuropathic pain meta-analysis (PMC12943413, N=688), and the peripheral nerve regeneration mechanism literature (PubMed 19371845). This is analogous to how tarsal tunnel syndrome PEMF protocols were derived from the carpal tunnel model — clinically validated by the identical pathophysiology.

Can PEMF be combined with orthotics or metatarsal padding?

Yes, and this is recommended. Orthotics and metatarsal padding reduce ongoing compressive load during the treatment course; PEMF addresses the existing nerve ischemia and inflammation. The combination reduces treatment duration compared to either modality alone. For clinic operators, the combination protocol creates a clear differentiation from single-modality physiotherapy offerings.